Clinical trial · Interventional
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After Induction Therapy of Rituximab Combined With Bendamustine (BR) or Cyclophosphamide, Vincristine, Doxorubicin, Prednisone (RCHOP) or Lenalidomide (R2): a Multicenter Clinical Study
NCT04842318CI-TRIAL-00051217unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multi-center clinical study will evaluate the efficacy of Rituximab maintenance treatment of newly diagnosed follicular lymphoma after induction therapy of BR, RCHOP or R2.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BR for 6 cycles +R for 8 cycles | Drug | — | UNRESOLVED |
| R2 for 6 cycles + R2 maintenance | Drug | — | UNRESOLVED |
| RCHOP for 6 cycles +R for 8 cycles | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- BR+R
- description
- Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
- interventionNames
- Drug: BR for 6 cycles +R for 8 cycles
- type
- EXPERIMENTAL
- label
- RCHOP+R
- description
- Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
- interventionNames
- Drug: RCHOP for 6 cycles +R for 8 cycles
- type
- EXPERIMENTAL
- label
- R2+R2
- description
- Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification * Treatment naive * Age ≥ 18 years * Indications for treatment confirmed * Must has measurable lesion in CT or PET-CT prior to treatment * Considered suitable for RCHOP, BR or R2 regimens * Informed consented Exclusion Criteria: * Transformed follicular lymphoma or 3B follicular lymphoma; * HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive * Central nervous system or meninges involved * Any drug contraindication in the treatment plan * Patients judged by other researchers to be unsuitable for inclusion in the study
References
Publications (0)
Data not yet available
No reference posted for this study.